Not long after changing its identity to The Nature’s Bounty Co. from NBTY Inc., Nature’s Bounty may be on the block.
Parent company The Carlyle Group is mulling a possible sale of the vitamins and dietary supplements brand, Bloomberg News reported.
Citing anonymous sources, the Bloomberg article said Carlyle has consulted potential advisers about selling Nature’s Bounty and the brand could attract up to $6 billion in a sale.
The report also said that Carlyle could peddle the brand’s international unit separately if unable to land a buyer for the entire business.
Meanwhile, Reuters reported (again citing anonymous sources) that Carlyle has retained Goldman Sachs to help it explore a sale of Nature’s Bounty, which generates about $3 billion in annual sales.
Ronkonkoma, N.Y.-based Nature’s Bounty has been a part of Carlyle’s portfolio for over six years. The asset management firm completed its $4 billion acquisition of then-NBTY in October 2010 after the deal was unveiled the previous July. At the time, the transaction was one of the biggest private equity deals in 2010.
Besides the name switch from NBTY, Nature’s Bounty in 2016 announced a joint venture with Hong Kong-based By-Health Co. Ltd. to drive the growth of the Nature’s Bounty and MET-Rx brands in China and agreed to sell its Vitamin World retail business to private investment firm Centre Lane Partners.
The supplement company’s roster of brands includes Nature’s Bounty, Sundown Naturals, Solgar, Holland & Barrett, Osteo Bi-Flex, Ester-C, MET-Rx, Pure Protein, Balance, Body Fortress, Puritan’s Pride and Dr. Organic.